B
Baker Bros. Advisors LP
+ HoldingVRNA
+23.44%
3M Return
$106.910
+0.118 (+0.11%)Al cierre
Loading chart…
- High
- 106.930
- Open
- 106.850
- VWAP
- 106.88
- Vol
- 1.87M
- Mkt Cap
- 1.25B
- Low
- 106.810
- Amount
- 200.08M
- EV/EBITDA, TTM
- 0.00
Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Analyst Ratings (4)
+0.08% upside
Buy
4 Buy
0 Hold
0 Sell
Current: 106.91
Mínimo
107.00
Promedio
107.00
Máximo
107.00
H.C. Wainwright
Neutral
$107
2025-07-14
H.C. Wainwright
2025-07-14
Precio objetivo
$107
Neutral
Roth Capital
Neutral
$107
2025-07-10
Roth Capital
2025-07-10
Precio objetivo
$107
Neutral
Wolfe Research
Peer Perform
—
2025-07-10
Wolfe Research
2025-07-10
Precio objetivo
—
Peer Perform
Truist
Hold
$107
2025-07-10
Truist
2025-07-10
Precio objetivo
$107
Hold
Piper Sandler
Neutral
$107
2025-07-10
Piper Sandler
2025-07-10
Precio objetivo
$107
Neutral
Métricas de valoración
The current forward P/E ratio for Verona Pharma PLC (VRNA) is 1243.39, compared to its 5-year average forward P/E of -77.15.
Whales holding VRNA
Cronología de eventos
Noticias
7.512-31BenzingaBiotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
3.010-07NASDAQ.COMQuantitative Stock Analysis of VRNA
8.510-07NewsfilterMerck Finalizes Purchase of Verona Pharma
8.510-06SeekingAlphaCourt Approves Merck's Acquisition of Verona Pharma
3.009-30NASDAQ.COMQuantitative Stock Analysis of VRNA
VRNA FAQ — answered by Alphio AI
Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
4 analysts cover VRNA: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 107.00.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.